Treatment received varied depending on the RAS/BRAF mutational status and location of the primary tumor; most patients (n = 116; 67.1%) received doublet CHT and an anti-EGFR agent, while 20 (11.6%) and 37 (21.4%) received triplet CHT (FOLFOXIRI) and bevacizumab or doublet CHT (FOLFOX/CAPEOX/FOLFIRI) and bevacizumab, respectively. This evidence concerns the gene BRAF and neoplasm.